The “Rule of 5” in chemistry is a set of guidelines used in drug design to predict whether a new compound can be taken as a pill and still get absorbed into the body. Developed by pharmaceutical scientist Christopher Lipinski while working at Pfizer, the rule says that a drug candidate is likely to have poor absorption if it violates two or more of four specific thresholds, all built around the number five or multiples of it.
The Four Thresholds
The Rule of 5 flags a compound as likely to be poorly absorbed when it has:
- More than 5 hydrogen bond donors (parts of the molecule that can give away a hydrogen atom to surrounding tissue)
- More than 10 hydrogen bond acceptors (parts that can receive a hydrogen atom)
- A molecular weight greater than 500 daltons (meaning the molecule is physically large)
- A LogP greater than 5 (a measure of how much the molecule prefers fat over water)
A compound that breaks just one of these rules may still work fine as an oral drug. The concern kicks in when two or more thresholds are crossed at once. That combination makes it increasingly unlikely the drug will pass through the lining of the gut and reach the bloodstream in useful amounts.
Why It’s Called the “Rule of Five”
Despite having four criteria, the name comes from the numbers themselves. Each cutoff is five or a clean multiple of it: 5 donors, 10 acceptors (5 × 2), molecular weight of 500 (5 × 100), and a LogP of 5. Lipinski published the original framework in 1997 after analyzing the properties of thousands of existing oral drugs and noticing that the ones that worked shared these general boundaries. The pattern was so consistent that it became one of the most widely used screening tools in early drug development.
What These Properties Actually Control
Each of the four criteria relates to how easily a molecule can cross biological membranes, particularly the wall of the small intestine. When you swallow a pill, the drug dissolves in your gut and needs to pass through layers of cell membranes to reach your blood. Those membranes are made of fat-like molecules, so getting through them requires a balance: the drug has to be water-soluble enough to dissolve in the gut, but fat-friendly enough to slip through the membrane.
Molecules that are too large (high molecular weight) physically struggle to squeeze through. Molecules that form too many hydrogen bonds with surrounding water cling to the watery environment of the gut and resist entering the fatty membrane. And molecules with a very high LogP are so fat-soluble that they may not dissolve well in the gut fluid in the first place, or they get trapped in fatty tissue instead of circulating in the blood. The Rule of 5 captures these tradeoffs in four simple numbers that chemists can check before ever synthesizing a compound.
Notable Exceptions
The Rule of 5 is a guideline, not a law, and several important drug classes break it routinely. Natural products and large ring-shaped molecules called macrocycles are the most common violators. Cyclosporine A, a widely used immunosuppressant, blows past most of the thresholds with its large molecular weight and complex structure, yet it works well as an oral medication. Several antiviral drugs, including some used to treat hepatitis C, also fall outside Rule of 5 boundaries.
These drugs get around the rules through clever molecular behavior. Some can change their three-dimensional shape depending on their environment, folding inward to hide their water-loving parts when crossing a fatty membrane, then opening up again once they reach water on the other side. Others rely on active transport systems, essentially hitching a ride on protein channels that carry molecules across cell membranes, rather than passively diffusing through on their own. The Rule of 5 only predicts passive absorption, so drugs that use these alternative routes can succeed despite violating the guidelines.
How It’s Used in Drug Development
Pharmaceutical chemists use the Rule of 5 as an early filter. When they have a molecule that shows promising activity against a disease target in the lab, they check it against these four criteria to gauge whether it has a realistic shot at becoming a pill. If the compound violates multiple rules, the team knows they either need to modify its structure to bring it back within bounds, explore alternative delivery methods like injection, or invest in specialized formulation strategies.
The rule remains one of the most referenced tools in medicinal chemistry, but it’s used alongside newer guidelines. Veber’s rules, introduced later, add two more criteria focused on molecular flexibility and surface area. An analysis of approved oral drugs found that about 66% conform to the Rule of 5, while roughly 85% follow Veber’s rules, suggesting the newer criteria may be slightly better at capturing what makes a successful oral drug. In practice, chemists treat both as useful starting points rather than rigid boundaries, since some of the most valuable drugs on the market exist precisely because researchers were willing to break the rules when the biology demanded it.